- Home
- FEBO vs MEIP Comparison
FEBO vs MEIP Comparison
Compare FEBO & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- MEIP
- Stock Information
- Founded
- FEBO 1993
- MEIP 2000
- Country
- FEBO Hong Kong
- MEIP United States
- Employees
- FEBO N/A
- MEIP N/A
- Industry
- FEBO
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- FEBO
- MEIP Health Care
- Exchange
- FEBO Nasdaq
- MEIP Nasdaq
- Market Cap
- FEBO 19.4M
- MEIP 16.3M
- IPO Year
- FEBO 2023
- MEIP 2003
- Fundamental
- Price
- FEBO $1.47
- MEIP $2.77
- Analyst Decision
- FEBO
- MEIP Hold
- Analyst Count
- FEBO 0
- MEIP 2
- Target Price
- FEBO N/A
- MEIP $7.00
- AVG Volume (30 Days)
- FEBO 57.8K
- MEIP 34.9K
- Earning Date
- FEBO 10-03-2024
- MEIP 02-11-2025
- Dividend Yield
- FEBO N/A
- MEIP N/A
- EPS Growth
- FEBO N/A
- MEIP N/A
- EPS
- FEBO N/A
- MEIP N/A
- Revenue
- FEBO $16,319,897.00
- MEIP N/A
- Revenue This Year
- FEBO N/A
- MEIP N/A
- Revenue Next Year
- FEBO N/A
- MEIP $300.00
- P/E Ratio
- FEBO N/A
- MEIP N/A
- Revenue Growth
- FEBO 9.01
- MEIP 33.76
- 52 Week Low
- FEBO $1.20
- MEIP $2.30
- 52 Week High
- FEBO $17.68
- MEIP $4.97
- Technical
- Relative Strength Index (RSI)
- FEBO 41.24
- MEIP 56.46
- Support Level
- FEBO $1.54
- MEIP $2.56
- Resistance Level
- FEBO $1.72
- MEIP $2.90
- Average True Range (ATR)
- FEBO 0.21
- MEIP 0.15
- MACD
- FEBO -0.00
- MEIP 0.03
- Stochastic Oscillator
- FEBO 8.20
- MEIP 75.47
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.